MorphoSys has expanded its therapeutic antibody collaboration with Pfizer through 2011, triggering a payment from Pfizer. Under the extended agreement, Pfizer has the option to begin new therapeutic antibody projects with MorphoSys, resulting in the potential for MorphoSys to receive development milestone payments exceeding $100 million. Further financial details were not disclosed. The agreement, originally signed in December 2003, was scheduled to end in December 2008. Under the extended ...